InsiderSignal.AI

InsiderSignal.ai

SGHT - Sight Sciences, Inc.

Insider Sale by Badawi Paul (Pres, CEO, 10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Badawi Paul, serving as Pres, CEO, 10% owner at Sight Sciences, Inc. (SGHT), sold 29,244 shares at $3.70 per share, for a total transaction value of $108,203.00. Following this transaction, Badawi Paul now holds 6,151,156 shares of SGHT.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Sight Sciences, Inc. operates in the HEALTHCARE sector, specifically within the MEDICAL DEVICES industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Badawi Paul

Pres, CEO, 10%

Paul Badawi is a co-founder, President, Chief Executive Officer, and Director of Sight Sciences, Inc. (SGHT), an ophthalmic medical device company headquartered in Menlo Park, California, specializing in surgical and nonsurgical technologies for eye diseases such as glaucoma and meibomian gland dysfunction.[[1]](https://fintool.com/app/research/companies/SGHT/people/paul-badawi)[[2]](https://www.zoominfo.com/p/Paul-Badawi/551785408)[[6]](https://www.sightsciences.com/us/team/) He co-invented key products including the OMNI® Surgical System, TearCare® System, VISCO360 Viscosurgical System, TRAB360 Trabeculotomy System, and Helix Microstent, and co-founded the company in 2011 with his brother, David Badawi, MD, the Chief Technology Officer.[[1]](https://fintool.com/app/research/companies/SGHT/people/paul-badawi)[[2]](https://www.zoominfo.com/p/Paul-Badawi/551785408)[[3]](https://www.ophthalmologytimes.com/view/what-s-your-wheye-a-conversation-with-paul-badawi-ceo-of-sight-sciences) Badawi holds an MBA from the University of California, Los Angeles (UCLA) Anderson School and a BS in Biological Sciences from the University of Chicago.[[1]](https://fintool.com/app/research/companies/SGHT/people/paul-badawi)[[2]](https://www.zoominfo.com/p/Paul-Badawi/551785408) Prior to Sight Sciences, he led the U.S. healthcare venture capital practice at 3i Group, managing investments in medical devices like Ulthera (acquired by Merz) and NeoGuide (acquired by Intuitive Surgical), and served as a Research Fellow in Biochemical Genetics at the National Institutes of Health.[[1]](https://fintool.com/app/research/companies/SGHT/people/paul-badawi)[[2]](https://www.zoominfo.com/p/Paul-Badawi/551785408)[[6]](https://www.sightsciences.com/us/team/) His leadership has earned him a CEO approval rating in the top 5% among peers.[[4]](https://www.comparably.com/companies/sight-sciences/ceo-rating)

View full insider profile →

Trade Price

$3.70

Quantity

29,244

Total Value

$108,203.00

Shares Owned

6,151,156

Trade Date

Wednesday, April 1, 2026

4 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 2 days after trade

HEALTHCAREMEDICAL DEVICES

About Sight Sciences, Inc.

Company Overview

No company information available
View news mentioning SGHT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5333956

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime